OncLive® On Air S13 Ep8: Oncology PER® Spectives: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
Jun 2, 2025
Rahul A. Sheth, an expert in interventional oncology, Yana Najjar, a leading medical oncologist, and Douglas Johnson, a melanoma research director, dive into cutting-edge melanoma treatments. They discuss the role of oncolytic viruses in overcoming immune checkpoint resistance and share insights from the IGNITE trial. The importance of interdisciplinary collaboration between medical oncologists and interventional radiologists in administering these therapies is highlighted. They also touch on safety, workflow challenges, and the promise of innovative combination therapies for advanced cases.
AI Snips
Chapters
Transcript
Episode notes
Oncolytic Viruses Trigger Systemic Immunity
- Immune checkpoint inhibitors have been central to advanced melanoma treatment for over a decade.
- Intratumoral oncolytic viral therapies now expand interventional radiologists' role by inducing systemic immune responses.
Approaches to Immunotherapy Resistance
- Anti-PD therapy resistance in melanoma is a major challenge, manifesting as primary or acquired resistance.
- Options include adding CTLA-4 or LAG-3 inhibitors, tumor infiltrating lymphocyte therapy, or switching to targeted therapies like BRAF/MEK inhibitors.
Engage IR Early for Intratumoral Therapy
- Engage local interventional radiologists early to discuss intratumoral therapies like RP1.
- Collaboration sparks excitement and ensures efficient delivery for melanoma patient injections.